Mirabegron in the treatment of overactive bladder

Bibliography

• Halen BT, de Ridder D, Freeman RM, et al. An international urogynecology association (IUGA)/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010;29:4-20
   PubMedGoogle Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-14
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008;101:1388-95
   PubMed Web of Science ®Google Scholar
• Griffiths D, Tadic SD. Bladder control, urgency, and urge incontinence: evidence from functional brain imaging. Neurourol Urodyn 2008;27:466-74
   PubMed Web of Science ®Google Scholar
• Robinson D, Cardozo L. Overactive bladder: diagnosis and management. Maturitas 2012;71:188-93
   PubMed Web of Science ®Google Scholar
• Leone Roberti Maggiore U, Salvatore S, Alessandri F, et al. Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. Expert Opin Drug Metab Toxicol 2012;8:1387-408
   PubMed Web of Science ®Google Scholar
• Irwin DE, Mungapen L, Milsom I, et al. The economic impact of overactive bladder syndrome in six Western countries. BJU Int 2009;103:202-9
   PubMed Web of Science ®Google Scholar
• Cisternas MG, Foreman AJ, Marshall TS, et al. Estimating the prevalence and economic burden of overactive bladder among Medicare beneficiaries prior to Medicare Part D coverage. Curr Med Res Opin 2009;25:911-19
   PubMed Web of Science ®Google Scholar
• Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 2012;110:1767-74
   PubMed Web of Science ®Google Scholar
• Marinkovic SP, Rovner ES, Moldwin RM, et al. The management of overactive bladder syndrome. BMJ 2012;344:e2365
   PubMed Web of Science ®Google Scholar
• Robinson D, Cardozo L. Overactive bladder: diagnosis and management. Maturitas 2012;71:188-93
   PubMed Web of Science ®Google Scholar
• Roe B, Ostaszkiewicz J, Milne J, Wallace S. Systematic reviews of bladder training and voiding programmes in adults: a synopsis of findings from data analysis and outcomes using metastudy technics. J Adv Nurs 2007;57:15-31
   PubMedGoogle Scholar
• Robinson D, Giarenis I, Cardozo L. The medical management of refractory Overactive Bladder. Maturitas 2013;74(4):386-90
   PubMedGoogle Scholar
• Leone Roberti Maggiore U, Scala C, Venturini PL, Ferrero S. Imidafenacin for the treatment of overactive bladder. Expert Opin Pharmacother 2013;14:1383-97
   PubMed Web of Science ®Google Scholar
• Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007;100:987-1006
   PubMed Web of Science ®Google Scholar
• Andersson KE. Bladder activation: afferent mechanisms. Urology 2002;59:43-50
   PubMed Web of Science ®Google Scholar
• Ferguson DR, Kennedy I, Burton TJ. ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes – a possible sensory mechanism? J Physiol 1997;505:503-11
   PubMed Web of Science ®Google Scholar
• Maggi CA. Prostanoids as local modulators of reflex micturition. Pharmacol Res 1992;25:13-20
   PubMed Web of Science ®Google Scholar
• Anderson KE. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993;45:253-308
   PubMed Web of Science ®Google Scholar
• Birder LA, Apodaca G, De Groat WC, Kanai AJ. Adrenergic- and capsaicin-evoked nitric oxide release from urothelium and afferent nerves in urinary bladder. Am J Physiol 1998;275:F226-9
   PubMed Web of Science ®Google Scholar
• Pandita RK, Mizusawa H, Andersson KE. Intravesical oxyhemoglobin initiates bladder overactivity in conscious, normal rats. J Urol 2000;164:545-50
   PubMed Web of Science ®Google Scholar
• Wiseman OJ, Fowler CJ, Landon DN. The role of the human bladder lamina propria myofibroblast. BJU Int 2003;91:89-93
   PubMed Web of Science ®Google Scholar
• Sui GP, Rothery S, Dupont E, et al. Gap junctions and connexin expression in human suburothelial interstitial cells. BJU Int 2002;90:118-29
   PubMedGoogle Scholar
• Fry CH, Sui GP, Kanai AJ, Wu C. The function of suburothelial myofibroblasts in the bladder. Neurourol Urodyn 2007;26:914-19
   PubMed Web of Science ®Google Scholar
• Swinburn P, Lloyd A, Ali S, et al. Preferences for antimuscarinic therapy for overactive bladder. BJU Int 2011;108:868-73
   PubMed Web of Science ®Google Scholar
• D'Souza AO, Smith MJ, Miller LA, et al. Persistence, adherence, and switch rates among extended-release and immedia terelease overactive bladder medications in a regional managed care plan. J Manag Care Pharm 2008;14:291-301
   PubMed Web of Science ®Google Scholar
• Benner JS, Nichol MB, Rovner ES, et al. Patient reported reasons for discontinuing overactive bladder medication. BJU Int 2010;105:1276-82
   PubMed Web of Science ®Google Scholar
• Otsuka A, Shinbo H, Hasebe K, et al. Effects of a novel beta(3)-adrenoceptor agonist, AJ-9677, on relaxation of the detrusor muscle: an in vitro study. Int J Urol 2008;15:1072-6
   PubMed Web of Science ®Google Scholar
• Ohlstein EH, von Keitz A, Michel MC. A multicenter, double-blind, randomized, placebo-controlled trial of the beta3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol 2012;62(5):834-40
   PubMed Web of Science ®Google Scholar
• Marinkovic SP, Rovner ES, Moldwin RM, et al. The management of overactive bladder syndrome. BMJ 2012;344:e2365
   PubMed Web of Science ®Google Scholar
• Robinson D, Giarenis I, Cardozo L. The management of overactive bladder refractory to medical therapy. Maturitas 2013;75:101-4
   PubMedGoogle Scholar
• Tyagi P, Thomas CA, Yoshimura N, Chancellor MB. Investigations into the presence of functional Beta1, Beta2 and Beta3-adrenoceptors in urothelium and detrusor of human bladder. Int Braz J Urol 2009;35:76-83
   PubMed Web of Science ®Google Scholar
• Andersson KE. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993;45:253-308
   PubMed Web of Science ®Google Scholar
• Michel MC, Vrydag W. Alpha1-, alpha2- and betaadrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006;147:S88-S119
   PubMed Web of Science ®Google Scholar
• Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 2004;84:935-86
   PubMed Web of Science ®Google Scholar
• Otsuka A, Shinbo H, Matsumoto R, et al. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol 2008;377:473-81
   PubMed Web of Science ®Google Scholar
• Yamaguchi O. Beta3-adrenoreceptors in human detrusor muscle. Urology 2002;59(5 Suppl 1):25-9
   PubMedGoogle Scholar
• Badawi JK, Seja T, Uecelehan H, et al. Relaxation of human detrusor muscle by selective beta-2 and beta-3 agonists and endogenous catecholamines. Urology 2007;69:785-90
   PubMed Web of Science ®Google Scholar
• Leon LA, Hoffman BE, Gardner SD, et al. Effects of the beta 3-adrenergic receptor agonist disodium 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl],3-benzodioxole-2,2-dicarboxylate (CL-316243) on bladder micturition reflex in spontaneously hypertensive rats. J Pharmacol Exp Ther 2008;326:178-85
   PubMed Web of Science ®Google Scholar
• Uchida H, Shishido K, Nomiya M, Yamaguchi O. Involvement of cyclic AMP-dependent and -independent mechanisms in the relaxation of rat detrusor muscle via betaadrenoceptors. Eur J Pharmacol 2005;518:195-202
   PubMedGoogle Scholar
• Frazier EP, Peters SL, Braverman AS, et al. Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 2008;377:449-62
   PubMed Web of Science ®Google Scholar
• Takemoto J, Masumiya H, Nunoki K, et al. Potentiation of potassium currents by beta-adrenoceptor agonists in human urinary bladder smooth muscle cells: a possible electrical mechanism of relaxation. Pharmacology 2008;81:251-8
   PubMedGoogle Scholar
• Hristov KL, Cui X, Brown SM, et al. Stimulation of beta3-adrenoceptors relaxes rat urinary bladder smooth muscle via activation of the large-conductance Ca2+ − activated K+ channels. Am J Physiol Cell Physiol 2008;295:1344-53
   Google Scholar
• Takasu T, Ukai M, Sato S, et al. Effect of (R)-[2-(2-aminothiazol-4-yl)-4′-2-[(2 hydroxy-2-phenylethyl)-amino]ethyl] acetanilide (YM178), a novel selective beta3 adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 2007;321:642-7
   PubMed Web of Science ®Google Scholar
• Noguchi Y, Someya A, Ukai M. Effects of mirabegron (YM178) on non-micturition contractions in the bladder of conscious rats with bladder outlet obstruction (BOO). J Urol [Proceedings of Annual Meeting of the American Urological Association (AUA)] 2009;81:abstract 25
   Google Scholar
• Gillespie J, Guilloteau V, Korstanje C, et al. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the beta(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction. BJU Int 2012;110:E132-42
   Web of Science ®Google Scholar
• Someya A, Ukai M, Yanai H. Mirabegron (YM178), a novel beta3-adrenoceptor (AR) agonist, increased functional bladder capacity and decreased micturition frequency in conscious waterloaded cynomolgus monkeys. Eur Urol Suppl [Proceedings of 25th Congress of the European Association of Urologists (April 16–20, 2010, Barcelona)] 9(2):abstract 266
   Google Scholar
• Sanford M. Mirabegron: a review of its use in patients with overactive bladder syndrome. Drugs 2013;73:1213-25
   PubMedGoogle Scholar
• Aizawa N, Homma Y, Igawa Y. Effects of mirabegron, a novel beta3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Eur Urol 2012;62:1165-73
   PubMed Web of Science ®Google Scholar
• Kashyap M, Tyagi P. The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. Expert Opin Drug Metab Toxicol 2013;9:617-27
   PubMed Web of Science ®Google Scholar
• Eltink C, Lee J, Schaddelee M, et al. Single dose pharmacokinetics and absolute bioavailability of mirabegron, a beta(3)-adrenoceptor agonist for treatment of overactive bladder. Int J Clin Pharmacol Ther 2012;50:838-50
   PubMed Web of Science ®Google Scholar
• Malik M, van Gelderen EM, Lee JH, et al. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. Clin Pharmacol Ther 2012;92(6):696-706
   PubMed Web of Science ®Google Scholar
• Krauwinkel W, van Dijk J, Schaddelee M, et al. Pharmacokinetic properties of mirabegron, a beta3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther 2012;34:2144-60
   PubMed Web of Science ®Google Scholar
• Takusagawa S, Yajima K, Miyashita A, et al. Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective beta3-adrenoceptor agonist. Xenobiotica 2012;42:957-67
   PubMed Web of Science ®Google Scholar
• Takusagawa S, van Lier JJ, Suzuki K, et al. Absorption, metabolism and excretion of [(14)C] mirabegron (YM178), a potent and selective beta(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos 2012;40:815-24
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta(3)-Adrenoceptor Agonist, in patients with Overactive Bladder: results from a randomized European-Australian Phase III trial. Eur Urol 2013;63:283-95
   PubMed Web of Science ®Google Scholar
• Nitti VW, Auerbach S, Martin N, et al. Results of a randomized Phase III trial of mirabegron in patients with overactive bladder. J Urol 2013;189:1388-95
   PubMed Web of Science ®Google Scholar
• Dickinson J, Lewand M, Sawamoto T, et al. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron. 2013;33:11-23
   Google Scholar
• Takusagawa S, Miyashita A, Iwatsubo T, Usui T. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective beta3-adrenoceptor agonist. Xenobiotica 2012;42:1187-96
   PubMed Web of Science ®Google Scholar
• Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled Phase III study to assess 12-month safety and efficacy of mirabegron, a beta(3)-Adrenoceptor agonist, in overactive bladder. Eur Urol 2013;63:296-305
   PubMed Web of Science ®Google Scholar
• Chapple C, Wyndaele JJ, Van Kerrebroeck P, et al. Dose-ranging study of once-daily mirabegron (Ym178), a novel selective beta3-adrenoceptor agonist. Patients With Overactive Bladder (OAB). European Urology Association Annual conference; Barcelona, Elsevier B.V.; 2010. p. 249
   Google Scholar
• Chapple CR, Amarenco G, López Aramburu MA, et al. BLOSSOM Investigator Group. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn 2013;32:1116-22
   PubMed Web of Science ®Google Scholar
• Chapple CR, Dvorak V, Radziszewski P, et al. Dragon Investigator Group. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J 2013;24:1447-58
   PubMed Web of Science ®Google Scholar
• Herschorn S, Barkin J, Castro-Diaz D, et al. A Phase III, randomized, doubleblind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the b3 adrenoceptor agonist, mirabegron in patients with symptoms of overactive bladder. Urology 2013;82:313-20
   PubMed Web of Science ®Google Scholar
• Khullar V, Cambronero J, Angulo JC, et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial. BMC Urol 2013;13:45
   PubMed Web of Science ®Google Scholar
• Otsuki H, Kosaka T, Nakamura K, et al. beta3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men. Int Urol Nephrol 2013;45:53-6
   PubMed Web of Science ®Google Scholar
• Malik M, van Gelderen EM, Lee JH, et al. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. Clin Pharmacol Ther 2012;92:696-706
   PubMed Web of Science ®Google Scholar
• Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract 2013;67:619-32
   PubMed Web of Science ®Google Scholar
• Astellas Pharma US, Inc. Myrbetriq™ (mirabegron) extended release tablets. US prescribing information. 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202611s000lbl.pdf [Accessed 12 December 2013]
   Google Scholar
• Astellas Pharma, Inc. Approval for Betanis tablet, a treatment for OAB in Japan [media release]. Available from: http://www.astellas.com/en/corporate/news/detail/approval-for-betanis-tablet-a.html [Accessed 12 December 2013]
   Google Scholar
• European Medicines Agency. Betmiga 25 mg and 50 mg prolonged-release tablets: summary of product characteristics. 2013. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002388/WC500137309.pdf [Accessed 12 December 2013]
   Google Scholar
• Astellas Pharma Canada, Inc. Astellas Pharma Canada, Inc. receives a Notice of Compliance from Health Canada for Myrbetriq™ (mirabegron) [media release]. Available from: http://www.cmsastellas.ca/uploads/pdf/131-2013-03-04-myrbetriq%20PM-Approved.pdf [Accessed 12 December 2013]
   Google Scholar
• Caremel R, Loutochin O, Corcos J. What do we know and not know about mirabegron, a novel beta3 agonist, in the treatment of overactive bladder? Int Urogynecol J 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Rodriguez M, Carillon C, Coquerel A, et al. Evidence for the presence of beta 3-adrenergic receptor mRNA in the human brain. Brain Res Mol Brain Res 1995;29:369-75
   PubMedGoogle Scholar
• Rosa GM, Bauckneht M, Scala C, et al. Cardiovascular effects of antimuscarinic agents in overactive bladder. Expert Opin Drug Saf 2013;12:815-27
   PubMed Web of Science ®Google Scholar
• Takasu T, Ukai M, Sato S, et al. Effect of (R)-[2-(2-aminothiazol-4-yl)-4′-2-[(2 hydroxy-2-phenylethyl)-amino]ethyl] acetanilide (YM178), a novel selective beta3 adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 2007;321:642-7
   PubMed Web of Science ®Google Scholar
• Noguchi Y, Someya A, Ukai M. Effects of mirabegron (YM178) on non-micturition contractions in the bladder of conscious rats with bladder outlet obstruction (BOO). J Urol [proceedings of Annual Meeting of the American Urological Association (AUA) (April 25–30, 2009, Chicago)] 2009;181(Suppl 4):abstract 25
   Google Scholar
• Gillespie J, Guilloteau V, Korstanje C, et al. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction. BJU Int 2012;110(2 Pt 2):E132-42
   PubMed Web of Science ®Google Scholar
• Nitti VW, Rosenberg S, Mitcheson DH, et al. Urodynamics and safety of the beta3-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol 2013;190:1320-7
   PubMed Web of Science ®Google Scholar
• Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) – efficacy results from a phase 2 study (symphony). J Urol 2013;189:e803
   PubMedGoogle Scholar
• Available from: http://www.clinicaltrials.gov/ ID protocol number: NCT01972841
   Google Scholar
• Gauthier C, Rozec B, Manoury B, Balligand JL. Beta-3 adrenoceptors as new therapeutic targets for cardiovascular pathologies. Curr Heart Fail Rep 2011;8:184-92
   PubMedGoogle Scholar
• Available from: http://www.chemspider.com/Chemical-Structure.8041219.html?rid=7c176481-bdec-4851-a93d-96f0b5692fa0 [Accessed 1 December 2013]
   Google Scholar